Skip to main content
. 2021 Mar 16;15(4):6326–6339. doi: 10.1021/acsnano.0c05792

Figure 4.

Figure 4

In vivo targeting of NP in two inflammation models. Increasing the protein content on NPs resulted in increased targeting in LLI and TNBC. (A) LLI and (F) TNBC diseased mice were treated with NPs as shown. Inflamed right ear (B) and tumor (G) targeting of fluorescent NPs were imaged by an in vivo imaging system (IVIS). Following 3–5 h from systemic administration, Leuko1:20 demonstrated significantly higher targeting in both in vivo models (C, H) across all NP formulations. These results were also verified using ex vivo analysis for both targeted organs (D–J). Results are shown as mean ± SEM. Either one-way (E, J) or two-way ANOVA (C, H) followed by Tukey’s multiple comparison test were used to determine statistical probabilities. P value ≤0.05 among means was considered as statistically significant.